We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMC icon
276
FMC
FMC
$1.25B
$513K 0.01%
7,775
-458
-6% -$28.1K
ARWR icon
277
Arrowhead Research
ARWR
$12.1B
$512K 0.01%
26,439
+6,978
+36% +$170K
PPLI
278
People Inc
PPLI
$3.12B
$509K 0.01%
11,526
-4,739
-29% -$197K
GHC icon
279
Graham Holdings Company
GHC
$5.31B
$507K 0.01%
+617
New +$468K
ALB icon
280
Albemarle
ALB
$13.4B
$506K 0.01%
5,342
-847
-14% -$75.2K
SEM
281
DELISTED
Select Medical
SEM
$505K 0.01%
+26,869
New +$515K
PLMR icon
282
Palomar
PLMR
$3.79B
$501K 0.01%
+5,292
New +$488K
S icon
283
SentinelOne
S
$6.35B
$500K 0.01%
+20,911
New +$472K
DXCM icon
284
DexCom
DXCM
$29B
$495K 0.01%
+7,391
New +$607K
LRN icon
285
Stride
LRN
$4.16B
$490K 0.01%
+5,746
New +$444K
KIDS icon
286
OrthoPediatrics
KIDS
$513M
$485K 0.01%
17,897
+10,825
+153% +$328K
CSTL icon
287
Castle Biosciences
CSTL
$742M
$483K 0.01%
16,943
-857,666
-98% -$21.8M
TAP icon
288
Molson Coors Class B
TAP
$8.02B
$478K 0.01%
+8,316
New +$445K
PRLB icon
289
Protolabs
PRLB
$1.7B
$476K 0.01%
16,210
-2,909
-15% -$88.8K
CRWD icon
290
CrowdStrike
CRWD
$183B
$476K 0.01%
+6,784
New +$482K
BA icon
291
Boeing
BA
$169B
$475K 0.01%
3,123
+45
+1% +$7.72K
FLGT icon
292
Fulgent Genetics
FLGT
$558M
$471K 0.01%
+21,690
New +$485K
SUI icon
293
Sun Communities
SUI
$15.8B
$471K 0.01%
+3,486
New +$458K
ADT icon
294
ADT
ADT
$5.43B
$468K 0.01%
+64,748
New +$475K
RMR icon
295
The RMR Group
RMR
$335M
$461K 0.01%
+18,170
New +$448K
TNET icon
296
TriNet
TNET
$3.23B
$460K 0.01%
+4,744
New +$472K
LFST icon
297
Lifestance Health
LFST
$4.15B
$454K 0.01%
+64,787
New +$389K
TDY icon
298
Teledyne Technologies
TDY
$29.2B
$450K 0.01%
1,028
-2,628
-72% -$1.09M
ORI icon
299
Old Republic International
ORI
$10.9B
$448K 0.01%
+12,645
New +$428K
CIVI
300
DELISTED
Civitas Resources
CIVI
$446K 0.01%
8,805
+5,180
+143% +$321K
10 11
12
13 14

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.